Filter
132
Filtered Results: 132
Text search:
praziquantel
treatment
Featured
Recommendations
23
New Publications
28
Language
Document type
Studies & Reports
45
No document type
36
Guidelines
21
Manuals
13
Strategic & Response Plan
7
Fact sheets
5
Brochures
3
Infographics
2
Countries / Regions
Tanzania
11
Global
9
South Africa
4
Uganda
4
Zimbabwe
3
Ethiopia
3
Sierra Leone
2
Nigeria
2
Senegal
2
Philippines
2
Latin America and the Carribbean
2
Namibia
2
Botswana
2
Liberia
2
Nepal
1
Kenya
1
Ukraine
1
Rwanda
1
Cameroon
1
Burkina Faso
1
Malawi
1
Mozambique
1
West and Central Africa
1
North America
1
East and Southern Africa
1
Sudan
1
Angola
1
Chad
1
Somalia
1
India
1
Myanmar / Burma
1
Madagascar
1
Authors & Publishers
Publication Years
Category
Countries
47
Clinical Guidelines
22
Public Health
8
Women & Child Health
3
Key Resources
2
Toolboxes
NTDs
69
Pharmacy
14
AMR
4
Planetary Health
2
Conflict
2
Mental Health
1
COVID-19
1
Caregiver
1
Health Financing Toolbox
1
NCDs
1
In 2014, an estimated 40 million women of reproductive age were infected with Schistosoma haematobium, S. japonicum and/or S. mansoni. In both 2003 and 2006, the World Health Organization (WHO) recommended that all schistosome-infected pregnant and breastfeeding women be offered treatment, with praz...
PLOS Glob Public Health 4(12): e0004035. https://doi. org/10.1371/journal.pgph.0004035.
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-
aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and
elimination program...
Infectious Diseases of Poverty (2020) 9:74
To detect acute schistosomiasis, low-intensity infections, or to verify the success of treatment with
praziquantel, highly sensitive test methods are required. The aim of this study was therefore to demonstrate the
performance of Schistosoma mansoni spec...
Front. Public Health 9:622809
The control and elimination of schistosomiasis have over the last two decades involved several strategies, with the current strategy by the World Health Organization (WHO) focusing mainly on treatment with praziquantel during mass drug administration (MDA). However, th...
Infographic
Disease: Infection is widespread in poor communities, 221 million people affected worldwide...
Affected Populations: Women, Children...
Prevention and Control: WHO recommends praziquantel for treatment of all forms of schistosomiasis...
BMC Infectious Diseases (2019) 19:832
Intestinal schistosomiasis is highly endemic in Tanzania and mass drug administration (MDA) using
praziquantel is the mainstay of the control program. However, the MDA program covers only school aged children
and does not include neither adult individuals nor...
The larval stage of the parasite Taenia solium can encyst in the central nervous system causing neurocysticercosis, which is the main cause of acquired epilepsy in the countries in which the parasite is endemic. Endemic areas are those with the presence (or likely presence) of the full life cycle of...
Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and intensity reduction rate (IRR). Here, ...
Schistosomiasis and soil-transmitted helminths (STH) infections are major public health problems. We aimed to study the 6-mo impact of mass drug administration with praziquantel and albendazole on urinary schistosomiasis and STH.We examined children (aged 2–15 y) from one hamlet, who provided urin...
Tis first edition describes the standard operating procedures for health products for NTDs amenable to preventive chemotherapy and the medicines donated to treat them. These include albendazole for lymphatic filariasis and soil-transmitted helminthiases; azithromycin for trachoma and yaws; diethylca...
Schweizerische Fachgesellschaft für Tropen‐ und Reisemedizin FMH
Cystic echinococcosis (CE) is a well-known neglected parasitic disease. However, evidence supporting the four current treatment modalities is inadequate, and treatment options remain controversial. The aim of this work is to analyse the available data to answer clinical questions regarding medical t...
The Pediatric Praziquantel Consortium was founded in July 2012 as the first international, non-profit, public-private partnership in schistosomiasis, supported by world leading experts in tropical parasitic infectious diseases.
Volume 1 covers emergency triage assessment and treatment, and acute care for a severely ill or acutely injured patient for approximately the first 24 hours of care. It describes the clinical procedures commonly used in emergency and acute care, and gives a summary of the medicines used and the step...
Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes (trematode
worms) of the genus Schistosoma. At least 249 million people required preventive treatment in
2012. Preventive treatment, which should be repeated over a number of years, will reduce and
prevent morbidity.
Issue Brief 45 NTDs Part 3 : Schistosomiasis
recommended
In this subsequent part of the issue brief on the NTD Toolbox you will learn about general strategies, roadmaps, key treatment guidelines, reports, and training material on Schistosomiasis
Biology, Diagnosis and Treatment, Epidemiology and Prevention
Schistosoma haematobium is a parasitic digenetic trematode responsible for schistosomiasis (also known as bilharzia). The disease is caused by penetration of the skin by the parasite, spread by intermediate host molluscs in stagnant waters, and can be treated by administration of praziquantel. Schis...
Parasite Epidemiology and Control Volume 27, November 2024, e00380
The planning and implementation of intervention measures against schistosomiasis, particularly mass administration, require knowledge of the current status of the infection. This is important for monitoring the impact of the interve...
